Latysheva E.A., Latysheva T.V., Martynova I.A. Evaluation of efficacy and safety of intravenous immunoglobulin IG VENA in patients with primary antibody synthesis immunodeficiency

· RAJ №1-2016

Latysheva E.A., Latysheva T.V., Martynova I.A.

Institute of Immunology, Moscow, Russia

Key words: primary immunodeficiency, replacement immunotherapy, intravenous immunoglobulin

Replacement immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully for the
treatment of primary immunodeficiency (PID) for over 60 years. During this time, a huge step forward in
purification and manufacturing methods has been made. In addition IVIG therapy has been approved for other
diseases and this number is steadily expanding causing an appearance of new IVIG on the pharmaceutical market.
These drugs vary in composition, manufacturing technology and, as a consequence, in safety, administration
rate, and efficacy. The new IVIG on the Russian market IG Vena was recently introduced. It has already proved
its safety and efficacy abroad. This article presents the experience of using the drug IG Vena in adults with PID
in immunopathology department of the Institute of Immunology FMBA Russia.